|
2024-05-30 |
2024-05-28 |
S
Sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
300,000
-14.7%
34.30
USD 10,290,000
|
300,000
-14.7%
|
34.30
|
USD 10,290,000
|
|
|
2023-08-30 |
2023-08-28 |
B
Purchase
|
VIKING GLOBAL INVESTORS LP
Large shareholder
|
511,627
+inf%
19.35
USD 9,899,982
|
511,627
+inf%
|
19.35
|
USD 9,899,982
|
|
|
2023-03-02 |
2023-03-01 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
400
-0.0%
24.71
USD 9,883
|
400
-0.0%
|
24.71
|
USD 9,883
|
|
|
2023-03-02 |
2023-03-01 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
39,600
-1.9%
24.20
USD 958,348
|
39,600
-1.9%
|
24.20
|
USD 958,348
|
|
|
2023-03-01 |
2023-02-28 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
60
-0.0%
25.02
USD 1,501
|
60
-0.0%
|
25.02
|
USD 1,501
|
|
|
2023-02-02 |
2023-02-02 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
1,130
-0.1%
25.89
USD 29,261
|
1,130
-0.1%
|
25.89
|
USD 29,261
|
|
|
2023-02-02 |
2023-02-02 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
10,120
-0.5%
25.40
USD 257,094
|
10,120
-0.5%
|
25.40
|
USD 257,094
|
|
|
2023-02-02 |
2023-02-01 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
693
-0.0%
25.66
USD 17,780
|
693
-0.0%
|
25.66
|
USD 17,780
|
|
|
2023-02-02 |
2023-02-01 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
14,608
-0.7%
25.08
USD 366,366
|
14,608
-0.7%
|
25.08
|
USD 366,366
|
|
|
2023-02-02 |
2023-02-01 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
13,449
-0.6%
24.29
USD 326,710
|
13,449
-0.6%
|
24.29
|
USD 326,710
|
|
|
2023-01-24 |
2023-01-24 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
63
-0.0%
26.11
USD 1,645
|
63
-0.0%
|
26.11
|
USD 1,645
|
|
|
2023-01-24 |
2023-01-24 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
4,272
-0.2%
25.71
USD 109,833
|
4,272
-0.2%
|
25.71
|
USD 109,833
|
|
|
2023-01-24 |
2023-01-23 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
21,665
-0.9%
25.36
USD 549,364
|
21,665
-0.9%
|
25.36
|
USD 549,364
|
|
|
2023-01-23 |
2023-01-23 |
PS
Planned sale
|
Kayyem Jon Faiz
Non-Executive Director
|
9,500
-0.3%
25.26
USD 239,999
|
9,500
-0.3%
|
25.26
|
USD 239,999
|
|
|
2023-01-04 |
2023-01-04 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
3,003
-0.1%
23.99
USD 72,043
|
3,003
-0.1%
|
23.99
|
USD 72,043
|
|
|
2023-01-04 |
2023-01-04 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
4,102
-0.2%
23.11
USD 94,786
|
4,102
-0.2%
|
23.11
|
USD 94,786
|
|
|
2023-01-04 |
2023-01-03 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
2,084
-0.1%
25.09
USD 52,293
|
2,084
-0.1%
|
25.09
|
USD 52,293
|
|
|
2023-01-04 |
2023-01-03 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
8,598
-0.4%
24.36
USD 209,426
|
8,598
-0.4%
|
24.36
|
USD 209,426
|
|
|
2023-01-04 |
2023-01-03 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
22,213
-1.0%
23.41
USD 520,051
|
22,213
-1.0%
|
23.41
|
USD 520,051
|
|
|
2022-12-22 |
2022-12-21 |
PS
Planned sale
|
Kayyem Jon Faiz
Non-Executive Director
|
1,959
-0.1%
27.61
USD 54,088
|
1,959
-0.1%
|
27.61
|
USD 54,088
|
|
|
2022-12-22 |
2022-12-21 |
PS
Planned sale
|
Kayyem Jon Faiz
Non-Executive Director
|
7,541
-0.2%
26.87
USD 202,591
|
7,541
-0.2%
|
26.87
|
USD 202,591
|
|
|
2022-12-20 |
2022-12-19 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
754
-0.0%
26.29
USD 19,820
|
754
-0.0%
|
26.29
|
USD 19,820
|
|
|
2022-12-20 |
2022-12-19 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
25,246
-1.0%
25.53
USD 644,624
|
25,246
-1.0%
|
25.53
|
USD 644,624
|
|
|
2022-12-07 |
2022-12-06 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
1,392
-0.1%
28.46
USD 39,617
|
1,392
-0.1%
|
28.46
|
USD 39,617
|
|
|
2022-12-07 |
2022-12-06 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
17,681
-0.8%
27.57
USD 487,493
|
17,681
-0.8%
|
27.57
|
USD 487,493
|
|
|
2022-12-07 |
2022-12-06 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
20,927
-1.0%
26.83
USD 561,572
|
20,927
-1.0%
|
26.83
|
USD 561,572
|
|
|
2022-11-22 |
2022-11-21 |
PS
Planned sale
|
Kayyem Jon Faiz
Non-Executive Director
|
6,767
-0.2%
30.12
USD 203,819
|
6,767
-0.2%
|
30.12
|
USD 203,819
|
|
|
2022-11-22 |
2022-11-21 |
PS
Planned sale
|
Kayyem Jon Faiz
Non-Executive Director
|
2,733
-0.1%
29.33
USD 80,153
|
2,733
-0.1%
|
29.33
|
USD 80,153
|
|
|
2022-11-18 |
2022-11-17 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
1,150
-0.0%
32.38
USD 37,241
|
1,150
-0.0%
|
32.38
|
USD 37,241
|
|
|
2022-11-18 |
2022-11-17 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
912
-0.0%
30.67
USD 27,969
|
912
-0.0%
|
30.67
|
USD 27,969
|
|
|
2022-11-18 |
2022-11-17 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
6,773
-0.3%
30.15
USD 204,196
|
6,773
-0.3%
|
30.15
|
USD 204,196
|
|
|
2022-11-18 |
2022-11-17 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
1,767
-0.1%
28.86
USD 50,991
|
1,767
-0.1%
|
28.86
|
USD 50,991
|
|
|
2022-11-18 |
2022-11-17 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
4,333
-0.2%
27.45
USD 118,937
|
4,333
-0.2%
|
27.45
|
USD 118,937
|
|
|
2022-11-18 |
2022-11-17 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
4,106
-0.2%
26.57
USD 109,098
|
4,106
-0.2%
|
26.57
|
USD 109,098
|
|
|
2022-11-18 |
2022-11-17 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
6,959
-0.3%
25.36
USD 176,477
|
6,959
-0.3%
|
25.36
|
USD 176,477
|
|
|
2022-11-02 |
2022-11-01 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
12,349
-0.6%
33.90
USD 418,641
|
12,349
-0.6%
|
33.90
|
USD 418,641
|
|
|
2022-11-02 |
2022-11-01 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
27,651
-1.2%
33.34
USD 921,746
|
27,651
-1.2%
|
33.34
|
USD 921,746
|
|
|
2022-10-24 |
2022-10-21 |
PS
Planned sale
|
Kayyem Jon Faiz
Non-Executive Director
|
5,928
-0.2%
30.58
USD 181,255
|
5,928
-0.2%
|
30.58
|
USD 181,255
|
|
|
2022-10-24 |
2022-10-21 |
PS
Planned sale
|
Kayyem Jon Faiz
Non-Executive Director
|
3,572
-0.1%
29.39
USD 104,977
|
3,572
-0.1%
|
29.39
|
USD 104,977
|
|
|
2022-10-18 |
2022-10-17 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
121
-0.0%
31.51
USD 3,812
|
121
-0.0%
|
31.51
|
USD 3,812
|
|
|
2022-10-18 |
2022-10-17 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
2,892
-0.1%
30.81
USD 89,090
|
2,892
-0.1%
|
30.81
|
USD 89,090
|
|
|
2022-10-18 |
2022-10-17 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
14,006
-0.5%
29.92
USD 419,123
|
14,006
-0.5%
|
29.92
|
USD 419,123
|
|
|
2022-10-18 |
2022-10-17 |
PS
Planned sale
|
Lappe Mark
Chief Executive Officer
Executive Director
|
8,981
-0.3%
28.66
USD 257,419
|
8,981
-0.3%
|
28.66
|
USD 257,419
|
|
|
2022-10-12 |
2022-10-07 |
B
Purchase
|
VIKING GLOBAL INVESTORS LP
Large shareholder
|
333,333
+inf%
30.00
USD 9,999,957
|
333,333
+inf%
|
30.00
|
USD 9,999,957
|
|
|
2022-10-12 |
2022-10-07 |
B
Purchase
|
VIKING GLOBAL INVESTORS LP
Large shareholder
|
1,000,000
+70.1%
30.00
USD 29,999,900
|
1,000,000
+70.1%
|
30.00
|
USD 29,999,900
|
|
|
2022-10-05 |
2022-10-04 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
100
-0.0%
30.52
USD 3,052
|
100
-0.0%
|
30.52
|
USD 3,052
|
|
|
2022-10-05 |
2022-10-04 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
10,893
-0.5%
29.68
USD 323,302
|
10,893
-0.5%
|
29.68
|
USD 323,302
|
|
|
2022-10-05 |
2022-10-04 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
5,954
-0.3%
28.97
USD 172,495
|
5,954
-0.3%
|
28.97
|
USD 172,495
|
|
|
2022-10-05 |
2022-10-04 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
4,262
-0.2%
27.76
USD 118,299
|
4,262
-0.2%
|
27.76
|
USD 118,299
|
|
|
2022-10-05 |
2022-10-04 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
11,136
-0.5%
26.78
USD 298,182
|
11,136
-0.5%
|
26.78
|
USD 298,182
|
|
|
2022-10-05 |
2022-10-04 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
6,207
-0.3%
26.06
USD 161,763
|
6,207
-0.3%
|
26.06
|
USD 161,763
|
|
|
2022-10-05 |
2022-10-04 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
1,448
-0.1%
24.67
USD 35,720
|
1,448
-0.1%
|
24.67
|
USD 35,720
|
|
|
2022-09-07 |
2022-09-06 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
2,493
-0.1%
15.66
USD 39,032
|
2,493
-0.1%
|
15.66
|
USD 39,032
|
|
|
2022-09-07 |
2022-09-06 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
37,507
-1.5%
14.86
USD 557,241
|
37,507
-1.5%
|
14.86
|
USD 557,241
|
|
|
2022-08-04 |
2022-08-03 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
15,500
-0.6%
18.47
USD 286,209
|
15,500
-0.6%
|
18.47
|
USD 286,209
|
|
|
2022-08-04 |
2022-08-02 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
24,500
-1.0%
17.70
USD 433,626
|
24,500
-1.0%
|
17.70
|
USD 433,626
|
|
|
2022-07-08 |
2022-07-07 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
40,000
-1.6%
17.17
USD 686,800
|
40,000
-1.6%
|
17.17
|
USD 686,800
|
|
|
2022-04-07 |
2022-04-05 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Officer
|
400
-0.0%
25.04
USD 10,016
|
400
-0.0%
|
25.04
|
USD 10,016
|
|
|
2021-03-24 |
2021-03-24 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Executive Director
|
17,000
-0.7%
19.02
USD 323,340
|
17,000
-0.7%
|
19.02
|
USD 323,340
|
|
|
2021-02-18 |
2021-02-17 |
PS
Planned sale
|
Wagner Klaus W.
Chief Medical Officer
Officer
|
19,559
-8.3%
25.29
USD 494,647
|
19,559
-8.3%
|
25.29
|
USD 494,647
|
|
|
2021-02-18 |
2021-02-16 |
PS
Planned sale
|
Wagner Klaus W.
Chief Medical Officer
Officer
|
156,474
-40.0%
24.32
USD 3,805,448
|
156,474
-40.0%
|
24.32
|
USD 3,805,448
|
|
|
2021-02-18 |
2021-02-16 |
PS
Planned sale
|
Eckelman Brendan P.
Chief Scientific Officer
Executive Director
|
17,000
-0.7%
25.90
USD 440,300
|
17,000
-0.7%
|
25.90
|
USD 440,300
|
|
|
2020-08-28 |
2020-08-26 |
B
Purchase
|
VIKING GLOBAL INVESTORS LP
Large shareholder
|
100,000
+7.5%
18.99
USD 1,898,700
|
100,000
+7.5%
|
18.99
|
USD 1,898,700
|
|
|
2020-08-28 |
2020-08-26 |
B
Purchase
|
VIKING GLOBAL INVESTORS LP
Large shareholder
|
80,219
+6.4%
18.84
USD 1,511,166
|
80,219
+6.4%
|
18.84
|
USD 1,511,166
|
|
|
2020-08-25 |
2020-08-25 |
B
Purchase
|
VIKING GLOBAL INVESTORS LP
Large shareholder
|
70,479
+6.0%
19.39
USD 1,366,588
|
70,479
+6.0%
|
19.39
|
USD 1,366,588
|
|
|
2020-08-25 |
2020-08-25 |
B
Purchase
|
VIKING GLOBAL INVESTORS LP
Large shareholder
|
14,825
+1.3%
19.23
USD 285,100
|
14,825
+1.3%
|
19.23
|
USD 285,100
|
|
|
2020-08-25 |
2020-08-24 |
B
Purchase
|
VIKING GLOBAL INVESTORS LP
Large shareholder
|
46,161
+4.1%
19.43
USD 897,001
|
46,161
+4.1%
|
19.43
|
USD 897,001
|
|
